Expanding the Applicability and Further Validating RapidAI: Russell Cerejo, MD
The vascular neurologist at Allegheny Health Network discussed ways to grow the RapidAI software and the need to conduct additional, large-scale research. [WATCH TIME: 3 minutes]
WATCH TIME: 3 minutes
"If something is new everyone is excited about it. But it has to show that there is benefit to it. We, in our limited experience, were able to present our data and show that there is benefit to using it.”
RapidAI is a telehealth software that combines advanced imaging and workflow to enable physicians in hospital settings to make faster, more accurate triage and/or transfer decisions for patients who present with stroke. It allows teams to streamline workflows and coordinate care throughout the patient journey while also capturing data that may identify trends. RapidAI has been used in nearly 2000 hospitals worldwide and is approved in more than 100 countries.
Despite its success, some clinicians, including Russell Cerejo, MD, believe there is still untapped potential. Cerejo, a vascular neurologist at Allegheny Health Network, recently presented 2 abstracts at the 2022 International Stroke Conference (ISC), held February 9-11, in New Orleans, Louisiana, that featured the use of RapidAI. He and his colleagues showed that the software has relatively high sensitivity and very high specificity in detecting intracranial hemorrhage, as well as high accuracy in detecting high grade stenosis and large vessel occlusion.1
Cerejo believes this is a system that can be implemented in various types of hospital settings, including ones that are smaller and rely on fewer staff, however, he believes that continued validation is also important. He sat down with NeurologyLive® to discuss the idea behind increasing applicability and expanding capabilities for RapidAI.
